Anti-epileptogenic Effects of Eslicarbazepine Acetate
Status:
COMPLETED
Trial end date:
2023-09-11
Target enrollment:
Participant gender:
Summary
This study aims to assess if eslicarbazepine acetate (ESL) treatment (started within 96 hours after stroke occurrence and continued for 30 days) changes the incidence of unprovoked seizures (USs) within the first 6 months after randomisation as compared to placebo